BACK <<     
 

 

Press Release Source: Aeolus Pharmaceuticals On Monday June 6, 2011, 2:00 pm EDT

NEW YORK,  June 6, 2011 /PRNewswire/ -- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that theirJune 2nd RetailInvestorConferences.com presentation is available for on-demand viewing.

LINK: www.retailinvestorconferences.com> Click the red "register/ watch event now" button.

Aeolus Pharmaceuticals' presentation will be available for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals is developing a new class of catalytic antioxidant compounds that protects healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with up to $140 million in funding by the US Government, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to efficiently develop the compound for use in oncology.

About RetailInvestorConferences.com:

RetailInvestorConferences.com, created by BetterInvesting (NAIC),PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

 
     
 
 
Copyright © 2001-2017. All Rights Reserved.